KemPharm to Host Detailed Investor Conference Call Plans for Pipeline Expansion | 2022-01-12 | Press Releases



Live audio conference call and webcast with slide presentation scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET

CELEBRATION, Florida, January 12, 2022 (GLOBE NEWSWIRE) – KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, Jan. 19, 2022, 4:30 p.m. ET, to discuss the company’s strategy & CloseCurlyQuote; to advance and expand its development pipeline. During the call, senior management will provide advice regarding KemPharm’s future clinical development priorities.

Conference Call Information:

Telephone access: To access the conference call by telephone, interested participants and investors must register via the following online form:

Once registered, all individuals will receive participant call numbers, an access code, and a registrant ID, which can then be used to access the conference call.

Participants can register at any time. It is recommended that the registration process be completed at least 15 minutes before the start of the call.

Webcast access: The live audio webcast with slide presentation will be accessible through the Investor Relations section of the KemPharm website ‘, An archive of the webcast and presentation will be available for 90 days beginning at approximately 5:30 p.m. ET on January 19, 2022.

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT.® (Ligand activated therapy). KemPharm uses its proprietary LAT® technology to generate improved prodrug versions of drugs approved by the FDA as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug pipeline is focused on high need areas of Attention Deficit Hyperactivity Disorder, or ADHD, Stimulant Use Disorder (SUD), and Rare CNS Diseases, including Idiopathic Hypersomnia (IH). Additionally, the United States Food and Drug Administration (FDA) has approved AZSTARYS®, a new once-daily treatment for ADHD in patents aged six and over containing KemPharm’s prodrug serdexmethylphenidate (SDX) and APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of KemPharm ‘hydrocodone and acetaminophen. For more information on KemPharm and its portfolio of prodrug product candidates, visit or contact us on Twitter, LinkedIn, Facebook and Youtube.

KemPharm contacts:

Tiberend Strategic Advisors, Inc.

Jason Rando / Maureen McEnroe, CFA

(212) 375-2665 / 2664

[email protected]

[email protected]

Main logo

Source link


Comments are closed.